Objectives: To determine the relationship between glycemic status and cognitive performance in men living with HIV (MLWH) and without HIV infection.
Introduction
The use of combination antiretroviral therapy (cART) has transformed HIV infection into a chronic illness and has markedly extended survival among people living with HIV (PLWH), often into old age [1] . However, the effect of cART on HIV-associated cognitive impairment is modest [2] [3] [4] . The prevalence of cognitive dysfunction among PLWH continues to be high [2, [5] [6] [7] , and the cause is not clear. Hypotheses include, but are not limited to, immune system integrity and inadequate control of persistent central nervous system HIV viral replication [8, 9] . In addition, chronic non-AIDS comorbidities such as impaired glucose regulation, which is common among PLWH [10] , may also play an important role in the pathogenesis of cognitive dysfunction [11] .
In the general population, type 2 diabetes mellitus (T2DM) has been associated with impairment in numerous cognitive domains [12] [13] [14] [15] [16] [17] . T2DM predominantly affects hippocampal-based declarative memory performance and attention, but psychomotor speed and executive functioning are also affected [13, 18] . The magnitude of cognitive decline depends largely on the duration of T2DM, glycemic control and antidiabetic agent use [19] [20] [21] [22] [23] [24] [25] . It has been reported that a 1% higher glycated hemoglobin (HbA1c) value is associated with significantly lower performance on psychomotor speed executive functioning and memory [26] .
In PLWH, the prevalence of T2DM is up to 14% [10] , compared with 9.4% in the US population [27] and associations between glycemic status and cognition have also been reported [28] . For example, in a prospective cohort enriched with older HIV-infected individuals, diabetes was associated with a five-fold increased odds of HIV-associated dementia compared with people without diabetes and this association remained significant after multivariable adjustment [29] . In the Women's Interagency HIV Study, greater insulin resistance was associated with poorer performance on Symbol Digit Modalities Test (SDMT), on Stroop Color-Naming and on Stroop Interference in unadjusted analyses [30] . Similar results were found using adjusted models in a more recent study of the same cohort [31] . In addition, the authors reported that women with T2DM had worse performance on measure of psychomotor speed and manual dexterity testing than women without T2DM [31] .
Despite evidence suggesting that glycemic status is associated with cognition in PLWH and without HIV, previous cross-sectional studies were limited in their ability to investigate longitudinal glycemic status with regard to trajectories of cognitive function over time [29, 30, 32] . In some cases, assessment of cognitive domains was not comprehensive [33, 34] and glycemic status was not adequately characterized [30, 31] . The purpose of the current study was to determine the longitudinal relationship between glycemic status and cognition using data from Multicenter AIDS Cohort Study (MACS), one of the largest ongoing cohorts of the natural and treated history of HIV among gay/bisexual men. The MACS has followed a neuropsychological subcohort for over 29 years, allowing for determination of the neurological and neurocognitive consequences of HIV over time [35] . We hypothesized that: glycemic status is associated with cognitive performance among men living with HIV (MLWH) and without HIV; the magnitude of this effect varies by cognitive domains; the duration of T2DM is associated with accelerated cognitive decline; and HIV-specific risk factors affect cognition in MLWH. [36, 37] . Eligibility criteria and follow-up procedures for the MACS have been described in detail previously [36, 38] . The current study included all participants who were active in the MACS between April 1999 and Oct 2016. Individuals whose primary language was not English or had any of the following conditions: a major neurologic or psychiatric illness, clinical stroke, dementia, learning disability, major head injury or brain opportunistic infection were excluded from the analysis. In addition, 72 men who became HIV infected during follow-up were excluded. The MACS protocol was approved by the institutional review board at each site. Informed consent was obtained from all participants.
Methods

Study participants
During semiannual visits, interviewer-administrated questionnaires were completed. Clinical assessment and biological specimens were obtained for laboratory determination of HIV/AIDS disease biomarkers. Reactive ELISAs, which were confirmed by western blot tests, were used to determine HIV serostatus. Plasma HIV-1 RNA levels were measured using the Roche Ultrasensitive RNA PCR assay (Hoffman-LaRoche, Nutley, New Jersey, USA) with a lower detection limit of 50 copies/ml. T-lymphocyte cell subset numbers and percentages were quantified using standardized flow cytometry [39] . For the purpose of analysis, the index visit was defined as the first visit at which participants had both metabolic assessment and neuropsychological evaluation.
Impaired fasting glucose and type 2 diabetes mellitus assessment Fasting serum glucose was measured at each semiannual visit beginning in April 1999, under the fasting protocol, which has been described previously [10] . Men were categorized as having impaired fasting glucose (IFG) if they had a fasting blood glucose level between 100 and 125 mg/dl. Self-reported T2DM was assessed using the following questions: 'Have you seen a doctor or other medical practitioner for any condition since your last visit? If yes, was there a diagnosis for your condition?' Current T2DM medication use was determined from a report of all medications used since the previous visit. Men were categorized as having T2DM if they: selfreported T2DM as a medical condition or took antidiabetic medications or fasting blood glucose level at least 126 mg/dl for two consecutive visits. T2DM was further dichotomized as controlled T2DM and uncontrolled T2DM if HbA1c less than 7.5% and HbA1c at least 7.5% confirmed at two consecutive visits, respectively. Men who were not categorized in any of the groups above were considered to have normal glucose level. Glycemic status was assessed for each individual at each followup visit.
Neuropsychological evaluation
Primary neurocognitive tests were the SDMT [40] and the Trail Making Test (TMT) Part A and B [41] . Part A of the TMT is a test of attention, motor speed and visuospatial tracking [34] . Part B of the TMT has all of the cognitive demands of TMT Part A, with an addition of a set-shifting component, which tests executive functioning. The TMT is sensitive to aging effects among the elderly [42] . The SDMT evaluates psychomotor speed, associative learning and incidental learning, and has demonstrated reliability independent of age, sex and socioeconomic status [43] . The full neuropsychological battery included the Grooved pegboard (nondominant hand) (GPN), a sensitive measure of manual dexterity [44] ; Rey Auditory Verbal Learning Test (RAVLT) [45] , immediate and delayed recall trials, assessing auditory learning and memory; Rey-Osterrieth Complex Figure (RCF) [46] , immediate and delayed recall trials, assessing visual learning memory; and the Stroop Test-Interference Trial (SIT) [47] , a measure of response inhibition, considered an executive function. The TMT and SDMT have been administered at each semiannual visit since 1 October 1991, and the full battery of neuropsychological tests every 2 years since 1 October 2005. These nine tasks were selected to be sensitive to most major areas of cognitive functioning. The validity/reliability of the above neuropsychological tests among PLWH have been reported in the previous studies [48, 49] .
Other covariates and risk factors Age (<40, 40-50 and >50 years old), race (white, Black and other) and education (college degree versus less than college) were demographics selected. Depressive symptoms were defined using the Center for Epidemiologic Studies Depression Scale more than 16; hypertension was defined as DBP at least 90 or SBP at least 140 or (selfreported/clinical diagnosis of hypertension and use of medications); hypercholesterolemia was defined as fasting total cholesterol (TC) at least 200 mg/dl or LDL at least 130 mg/dl or HDL less than 40 mg/dl or triglycerides at least 150 mg/dl or use of lipid-lowering medications with self-reported/clinical diagnosis in the past; hepatitis C virus (HCV) infection was considered present if a participant's serum HCV antibody and HCV RNA (COBAS AmpliPrep TaqMan HCV Assay) were positive; intravenous drug users (IVDU) and cocaine use were determined based on questions 'Took/used drugs with a needle since last visit?' and 'Used crack or any form of cocaine since last visit?', respectively; BMI was calculated using weight (kg)/[height (m)] 2 : less than 18.5 is considered underweight, 18.5 to less than 25 is normal, 25.0 to less than 30 is overweight and at least 30.0 is obese. Participants were asked if they currently smoke at each visit and former smokers would be those who answered yes and then no at a later visit. All covariates were updated by participants at each follow-up visit.
Statistical analysis
Comparisons of baseline characteristics, stratified by HIV serostatus, were performed using Student t tests for normally distributed continuous variables, Wilcoxon rank-sum tests for variables with skewed distributions and chi-square tests for categorical data. All neuropsychological test scores were transformed and summarized as z-scores with adjustment for learning effect, age and education. A higher z-score indicated better cognitive performance.
The association of glycemic status with cognition was examined using linear mixed models with random intercept allowed. This approach assessed within-individual changes in neuropsychological test scores from baseline to the end of the study period, accounting for within-person correlations. The analysis used all personvisits for three primary outcomes: SDMT, TMT-A and TMT-B, and six secondary outcomes from the tests in the full battery of neuropsychological tests. For the initial models, the performance of each neuropsychological test was a function of follow-up time, glycemic status, HIV serostatus and potential confounders. The interaction of follow-up time Ã glycemic status was then added to examine if there was an association of glycemic status and changes in cognitive performance over time. To assess the effect of cumulative exposure to glycemic impairment on cognition, the diabetes mellitus group was further categorized according to the percentage of time under observation during which diabetes mellitus was uncontrolled. This analysis used the same linear mixed model format from the initial model. Lastly, subgroup analysis was performed among MLWH to examine the role of nadir CD4 þ T-cell count (<200, 200-500, >500 cells/ml), undetectable HIV RNA and time on cART (in years), with the same covariate adjustments from the initial model. Analyses were performed using Stata 14.0 SE (StataCorp, College Station, Texas, USA).
Results
Demographic characteristics
In total, 1149 MLWH and 900 men without HIV were included, with a mean follow-up of 13 (AE4) years. Compared with men without HIV, MLWH tended to be younger, were more likely to be Black, obese, current smokers, cocaine users, infected with HCV, to have reported hypertension, depressive symptoms, hypercholesterolemia, but less likely to have college education (Table 1) . At baseline, MLWH were also more likely to have abnormalities in glucose metabolism than the men without HIV, though no statistically significant differences in IVDU status, glucose level, use of diabetes mellitus medications and diabetes mellitus duration were found by HIV serostatus.
Cognitive performance test results
At baseline, except for TMT-A, RAV-sum of learning trails, RAV-delayed recall and GPN, MLWH demonstrated significantly poorer performance on all neuropsychological tests than men without HIV (Table 2) . Longitudinally, linear mixed models indicated that factors associated with lower performance in all nine neuropsychological tests included being Black, the presence of depressive symptoms, IVDU and current smoking, whereas other risk factors including education, cocaine use, hypercholesterolemia, HCV infection, BMI and older age differed in their associations across cognitive domains (Table 3) .
Psychomotor speed and attention TMT-A, SDMT and GPN primarily evaluate psychomotor speed and attention (Table 3) . Men with uncontrolled T2DM had significantly worse performance on TMT-A (Coef. ¼ À0.137, P < 0.001) and SDMT (Coef. ¼ À0.121, P ¼ 0.001) compared with men with normal glucose, regardless of HIV serostatus, equivalent to the effect of 3.9 and 8.8 years of aging (derived from coefficient estimation of age parameter) on psychomotor 1852 AIDS 2018, Vol 32 No 13 speed and attention, respectively. Men with controlled T2DM (Coef. ¼ À0.219, P < 0.001) and IFG (Coef. ¼ À0.027, P ¼ 0.014) also had worse neuropsychological scores on GPN and SDMT, respectively, than men with normal glucose. However, no associations were observed on the following: IFG on both TMT-A and GPN, controlled T2DM on SDMT and TMT-A and uncontrolled diabetes mellitus on GPN. Current smoking, Black race and IVDU were associated with worse performance, whereas being overweight/obese seemed to have a protective effect on cognition regardless of HIV serostatus. Further analysis with the interaction has shown a significant cognitive decline in IFG, controlled and uncontrolled T2DM compared with normal glucose on TMT-A. A similar pattern was also found among both controlled and uncontrolled T2DM compared with normal glucose on SDMT and GPN (data not shown).
Executive function SIT and TMT-B are considered measures of executive function (Table 3) . Only men with uncontrolled diabetes mellitus (Coef. ¼ À0.077, P ¼ 0.048) had significantly poorer executive function, measured by TMT-B, than men with normal glucose, an equivalent effect of 1.8 years of aging. Worse performance was observed for TMT-B but not for SIT in association with current smoking and Black race. Significant cognitive decline over time was observed in both controlled and uncontrolled T2DM compared with normal glucose on TMT-B.
Verbal learning and memory RAVLT (Sum of Learning Trails & Delayed Recall) and RCF (Copy & Delayed Recall) assess verbal learning and visuospatial memory (Table 3) . Only men with controlled diabetes mellitus (Coef. ¼ À0.114, P ¼ 0.008) had worse cognitive performance on RAVLT (Sum of Learning Trails) than men with normal glucose, a difference similar to 9 years of aging on verbal learning and memory, though no significant associations were observed on RAVLT (Delayed recall) or RCF. Current smoking status, Black race and IVDU were associated with worse cognitive performance, whereas hypercholesterolemia showed a protective effect on cognition.
Type 2 diabetes mellitus disease duration
Among men with diabetes mellitus, disease duration was further categorized as the percentage of time with diabetes mellitus being uncontrolled over the study period (0, 0 to <30, 30 to <70, 70 to <100, 100%), according to quintiles. The impact of glycemic status on cognition was predominantly seen among men who had uncontrolled T2DM more than 70% of the time (Table 4) (Table 5) . Moreover, men with nadir CD4 þ T-cell counts below 200 cells/ml (Coef. ¼ À0.157, P ¼ 0.006) had significantly worse cognitive performance on TMT-A than men with counts above 500 cells/ml. However, neither having undetectable HIV-1 RNA nor length of cART showed a significant relationship with cognition.
Discussion
Our data support the hypothesis that abnormalities in glucose metabolism are associated with neuropsychological dysfunction among MLWH and without HIV. glycemic control and longer duration of T2DM. In the current study, T2DM was associated with cognitive performance on all the domains. IFG affected psychomotor speed/attention but had a less profound impact on cognition compared with T2DM. Of the nine cognitive tests, the TMT and SDMT appeared to be affected most, demonstrating an increased risk of psychomotor inefficiency, attention deficits and visuospatial tracking problems. Moreover, our results indicate a significant association between longer T2DM duration and cognitive dysfunction, suggesting that optimization of glycemic control and management of vascular disease risk factors may improve cognitive performance.
Greater cognitive impairment was correlated with poor
Although the affected cognitive domains differ across studies, the magnitude of observed impairment reported in people without HIV in general support our findings [50] [51] [52] [53] [54] [55] [56] . Specifically, a systematic review reported that memory, processing speed and cognitive flexibility were most consistently affected by diabetes across studies [57] . Among PLWH, increasing insulin resistance negatively affected attention and recognition among women after multivariable adjustment [31] .
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We also found that duration of T2DM was a strong predictor of cognitive performance, which is consistent with previous studies [20, 21, 58, 59] . A population-based case-control study reported that for participants with a duration of diabetes mellitus for 10 years or longer, their odds of having mild cognitive impairment were significantly elevated, 1.8 fold greater, compared with persons with duration of diabetes mellitus less than 10 years [59] . Similarly, community-dwelling elderly individuals in the highest HbA1c tertile were found to have significantly poorer overall cognition, semantic categorization and executive functioning, whereas such an association was not revealed in the lowest HbA1c tertile, which highlighted the importance of glycemic control in reducing the risk of cognitive decline [22] .
In the current study, IFG appeared to be less related than T2DM to cognition, as only mild impairment was observed on psychomotor speed among people with IFG, which has been seen in other studies [60, 61] . However, associations reported between IFG and cognition have varied in the literature [62] [63] [64] [65] . A pooled cohort analysis that included 8447 individuals from the general population reported that neither elevated fasting glucose levels nor insulin resistance was associated with executive function and memory in older people without a history of diabetes mellitus, whereas individuals with diabetes mellitus were noted to have cognitive decline [66] . In contrast, an analysis from a 4-year study of postmenopausal women reported that IFG increased the risk of developing cognitive dysfunction approximately two fold [67] . Hence, future studies are warranted to investigate whether there are thresholds for effects of dysglycemia on cognition.
We found that HIV stage of disease-related factors such as CD4 þ nadir were more informative than HIV serostatus regarding cognition in the cART era. A prospective cohort study that consisted of 1525 PLWH demonstrated that the odds of neurocognitive impairment were reduced by 10% for every 5-U increase in square-root CD4 þ nadir [68] . Heaton et al. [69] compared the incidence and characteristics of HIV-associated neurocognitive disorders before and during the cART era and found that low nadir CD4 þ was associated with neurocognitive dysfunction in both eras, whereas duration of HIV infection and viral suppression predicted impairment only before the cART era, a finding corroborative of our data. These findings support the importance of early cART initiation for disease avoidance, which may help preserve cognition in the long term.
Impaired glucose regulation plays a crucial role in the pathogenesis of cognitive decline, along with vascular risk factors, socioeconomic and lifestyle factors and depression. Several studies have demonstrated that prediabetes mellitus stage leads to a higher incidence of cognitive impairment [70, 71] or dementia [58, 72] and T2DM increases the incidence of vascular [73] [74] [75] and Alzheimer dementia [75] [76] [77] . Increased amyloid processing in the setting of hyperglycemia has been proposed as an underlying mechanism [78] . Other potential mechanisms include increased formation of advanced glycation end products, diacylglycerol activation of protein kinase C and increased glucose shunting in the hexosamine pathway of hyperglycemia, which have been shown to alter function in other organs, but whether similar effects occur in the brain is unclear [79] [80] [81] .
Multifactorial treatment approaches that target shared causes of diverse vascular disease risk factors, together with lifestyle changes (i.e. weight control, nutrition education) [82, 83] , may be necessary to prevent cognitive decline. A review has recommended that lifestyle intervention in middle-aged persons should be implemented along with medication for glycemic control to prevent cognitive decline [84] . For persons with a longstanding T2DM, maintaining good glycemic control may modulate the effect of diabetes mellitus on cognition.
To our knowledge, this report represents the largest and most comprehensive evaluation to date of the relationship between glycemic status and cognitive function among MLWH and without HIV. Strengths of our study are its prospective design and long follow-up period with repeated measurement of cognitive function using a sensitive test battery and repeated measures of covariates that allowed us to adjust for a broad array of potential confounders. Our study had several limitations. First, the MACS cohort includes only male participants; additional studies are needed to determine if similar results are observed in women with and without HIV. As multiple, inter-related factors contribute to cognitive performance, understanding the causal pathway of T2DM to cognitive impairment warrants future studies. Further, survivorship bias may have existed in the cohort; some MACS participants have been studied for more than 20 years, whereas those who suffered from more severe HIVrelated comorbidities may have been more likely to have dropped out. Lastly, the prevalence of T2DM was high in our cohort, possibly due to extensive ART treatment experience, especially exposure to toxic older ART drugs, and more prolonged untreated HIV infection prior to ART initiation. The generalizability of our results to other cohorts with less treatment experience and shorter HIV infection duration is unclear.
In conclusion, abnormal glucose regulation is associated with worse cognitive performance among both MLWH and without HIV. Glucose-mediated processes and duration of diabetic disease appear to be crucial, and therefore optimization of glycemic control appears to be an important goal for the maintenance of cognitive performance, along with control of other chronic vascular disease risk factors and lifestyle changes. The optimal timing of interventions aimed at improvements in glycemic control cannot be ascertained with precision from these data, but such interventions may be more effective when initiated in midlife than at a more advanced age.
